Search research articles
Contact Us
Filters
Showing results (201-210 of 263) with videos related to
Page
of 27
Sort By:
Therapeutic Advances in Infectious Disease
|
September 18, 2024
Clinical and diagnostic features of central nervous system tuberculosis in Indian children - a descriptive study
Bella Devaleenal Daniel, Elilarasi Selladurai, Sarath Balaji, et al.
Pediatric Research
|
May 3, 2025
Social epidemiology of sports and extracurricular activities in early adolescents
Jason M Nagata, Jennifer H Wong, Christiane K Helmer, et al.
Clinical Pharmacokinetics
|
March 10, 2018
A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women
Stein Schalkwijk, Rob Ter Heine, Angela C Colbers, et al.
Pharmacogenetics and Genomics
|
February 17, 2025
Pharmacogenetics of plasma dolutegravir exposure during 1-month rifapentine/isoniazid treatment of latent tuberculosis
Nia Covington, Anne F Luetkemeyer, Marjorie Z Imperial, et al.
Antimicrobial Agents and Chemotherapy
|
August 7, 2019
Delamanid Central Nervous System Pharmacokinetics in Tuberculous Meningitis in Rabbits and Humans
Elizabeth W Tucker, Lisa Pieterse, Matthew D Zimmerman, et al.
The Lancet. HIV
|
December 4, 2025
Fixed-dose combination bictegravir-emtricitabine-tenofovir alafenamide twice-daily for treatment of HIV during rifampicin-based tuberculosis treatment (INSIGHT Study): a phase 2b, open-label, randomised non-comparative trial
Anushka Naidoo, Kogieleum Naidoo, Marothi P Letsoalo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
July 21, 2022
Decreased Dolutegravir and Efavirenz Concentrations With Preserved Virological Suppression in Patients With Tuberculosis and Human Immunodeficiency Virus Receiving High-Dose Rifampicin
Christine Sekaggya-Wiltshire, Ruth Nabisere, Joseph Musaazi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 29, 2019
Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial
Kelly E Dooley, Richard Kaplan, Noluthando Mwelase, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences
|
September 20, 2022
The Association Between Midlife Leisure-Time Physical Activity and Hearing Loss in Late Life in the Atherosclerosis Risk in Communities Study
Pablo Martinez-Amezcua, Emmanuel Garcia Morales, Kelley P Gabriel, et al.
Antimicrobial Agents and Chemotherapy
|
August 22, 2018
Effect of Diabetes Mellitus on the Pharmacokinetics and Pharmacodynamics of Tuberculosis Treatment
Omamah Alfarisi, Vidya Mave, Sanjay Gaikwad, et al.
Page
of 27
Search research articles
Search
Showing results (201-210 of 263) with videos related to
Sort By:
Page
of 27
Therapeutic Advances in Infectious Disease
|
September 18, 2024
Clinical and diagnostic features of central nervous system tuberculosis in Indian children - a descriptive study
Bella Devaleenal Daniel, Elilarasi Selladurai, Sarath Balaji, et al.
Pediatric Research
|
May 3, 2025
Social epidemiology of sports and extracurricular activities in early adolescents
Jason M Nagata, Jennifer H Wong, Christiane K Helmer, et al.
Clinical Pharmacokinetics
|
March 10, 2018
A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women
Stein Schalkwijk, Rob Ter Heine, Angela C Colbers, et al.
Pharmacogenetics and Genomics
|
February 17, 2025
Pharmacogenetics of plasma dolutegravir exposure during 1-month rifapentine/isoniazid treatment of latent tuberculosis
Nia Covington, Anne F Luetkemeyer, Marjorie Z Imperial, et al.
Antimicrobial Agents and Chemotherapy
|
August 7, 2019
Delamanid Central Nervous System Pharmacokinetics in Tuberculous Meningitis in Rabbits and Humans
Elizabeth W Tucker, Lisa Pieterse, Matthew D Zimmerman, et al.
The Lancet. HIV
|
December 4, 2025
Fixed-dose combination bictegravir-emtricitabine-tenofovir alafenamide twice-daily for treatment of HIV during rifampicin-based tuberculosis treatment (INSIGHT Study): a phase 2b, open-label, randomised non-comparative trial
Anushka Naidoo, Kogieleum Naidoo, Marothi P Letsoalo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
July 21, 2022
Decreased Dolutegravir and Efavirenz Concentrations With Preserved Virological Suppression in Patients With Tuberculosis and Human Immunodeficiency Virus Receiving High-Dose Rifampicin
Christine Sekaggya-Wiltshire, Ruth Nabisere, Joseph Musaazi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 29, 2019
Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial
Kelly E Dooley, Richard Kaplan, Noluthando Mwelase, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences
|
September 20, 2022
The Association Between Midlife Leisure-Time Physical Activity and Hearing Loss in Late Life in the Atherosclerosis Risk in Communities Study
Pablo Martinez-Amezcua, Emmanuel Garcia Morales, Kelley P Gabriel, et al.
Antimicrobial Agents and Chemotherapy
|
August 22, 2018
Effect of Diabetes Mellitus on the Pharmacokinetics and Pharmacodynamics of Tuberculosis Treatment
Omamah Alfarisi, Vidya Mave, Sanjay Gaikwad, et al.
Page
of 27